EP1984004A4 - Glucane permettant d'améliorer une thérapie - Google Patents
Glucane permettant d'améliorer une thérapieInfo
- Publication number
- EP1984004A4 EP1984004A4 EP07718218A EP07718218A EP1984004A4 EP 1984004 A4 EP1984004 A4 EP 1984004A4 EP 07718218 A EP07718218 A EP 07718218A EP 07718218 A EP07718218 A EP 07718218A EP 1984004 A4 EP1984004 A4 EP 1984004A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapy
- glucan
- enhancing
- enhancing glucan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001503 Glucan Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/334,763 US7906492B2 (en) | 2001-01-16 | 2006-01-17 | Therapy-enhancing glucan |
PCT/US2007/001427 WO2007084661A2 (fr) | 2006-01-17 | 2007-01-17 | Glucane permettant d'améliorer une thérapie |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1984004A2 EP1984004A2 (fr) | 2008-10-29 |
EP1984004A4 true EP1984004A4 (fr) | 2010-03-03 |
Family
ID=40382391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07718218A Withdrawn EP1984004A4 (fr) | 2006-01-17 | 2007-01-17 | Glucane permettant d'améliorer une thérapie |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1984004A4 (fr) |
JP (1) | JP2009528267A (fr) |
AU (1) | AU2008207369B2 (fr) |
WO (1) | WO2007084661A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
JP5153188B2 (ja) * | 2007-03-30 | 2013-02-27 | 小林製薬株式会社 | Th1/Th2バランス改善剤 |
EP2219655A2 (fr) * | 2007-11-13 | 2010-08-25 | Biotec Pharmacon ASA | Procédés de traitement ou de prévention de maladies inflammatoires du tractus intestinal |
WO2012014978A1 (fr) * | 2010-07-29 | 2012-02-02 | 国立大学法人北海道大学 | Adjuvant immunitaire |
JP5990752B2 (ja) * | 2011-01-31 | 2016-09-14 | オリンパス株式会社 | 抗体療法の効果増強剤 |
JP6416751B2 (ja) | 2012-04-30 | 2018-10-31 | バイオセラ インコーポレイテッド | β−グルカン免疫治療方法 |
EP2832360A1 (fr) | 2013-07-30 | 2015-02-04 | Fresenius Kabi Deutschland GmbH | Polysaccharide pour utilisation dans la prévention de la formation de métastases et/ou de rechute |
JP6893594B2 (ja) * | 2014-07-10 | 2021-06-23 | ハイバーセル,インク. | 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン |
WO2018156888A1 (fr) | 2017-02-24 | 2018-08-30 | Biothera Pharmaceuticals, Inc. | Immunopharmacodynamie de bêta-glucane |
KR20210038839A (ko) * | 2018-03-13 | 2021-04-08 | 히버셀, 인크. | 베타 글루칸 및 cd40 효능제 조합 면역요법 |
CA3097980A1 (fr) | 2018-04-24 | 2019-10-31 | Memorial Sloan Kettering Cancer Center | Procedes d'amelioration de l'immunogenicite de vaccins specifiques d'un antigene faiblement immunogenes a l'aide de beta-glucanes de levure oraux |
WO2020061203A1 (fr) * | 2018-09-21 | 2020-03-26 | Nantcell, Inc. | Procédés et compositions pour moduler des cellules suppressives d'origine myéloïde |
JP7048102B2 (ja) | 2019-05-23 | 2022-04-05 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817643A (en) * | 1992-08-21 | 1998-10-06 | Alpha-Beta Technology, Inc. | Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same |
WO2002058711A1 (fr) * | 2001-01-16 | 2002-08-01 | Sloan-Kettering Institute For Cancer Research | Glucane ameliorant une therapie |
WO2005018544A2 (fr) * | 2003-07-16 | 2005-03-03 | Sloan-Kettering Institute For Cancer Research | Glucane renforçateur de therapie |
US20060009419A1 (en) * | 2002-09-04 | 2006-01-12 | Ross Gordon D | Therapy-enhancing glucan |
WO2006119395A2 (fr) * | 2005-05-03 | 2006-11-09 | Biopolymer Engineering, Inc. | Compositions d'association d'agents therapeutiques, et leurs procedes d'utilisation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340080C (fr) * | 1985-03-11 | 1998-10-13 | Dorothee Herlyn | Methode de traitement des tumeurs chez l'humain |
AU650626B2 (en) * | 1989-09-08 | 1994-06-30 | Alpha-Beta Technology, Inc. | Method for producing soluble glucans |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
EP0640348A1 (fr) * | 1993-07-26 | 1995-03-01 | Akzo Nobel N.V. | Mélange adjuvant à base d'huile et à base d'eau |
NO300692B1 (no) * | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan |
BR9708387A (pt) * | 1996-03-28 | 2000-01-04 | Genitrix Llc | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. |
JP2004507446A (ja) * | 2000-02-04 | 2004-03-11 | トーマス・ジェファーソン・ユニバーシティ | 低用量ハプテン化腫瘍細胞および腫瘍細胞抽出物の免疫治療 |
GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
-
2007
- 2007-01-17 WO PCT/US2007/001427 patent/WO2007084661A2/fr active Application Filing
- 2007-01-17 EP EP07718218A patent/EP1984004A4/fr not_active Withdrawn
- 2007-01-17 JP JP2008551413A patent/JP2009528267A/ja active Pending
-
2008
- 2008-08-18 AU AU2008207369A patent/AU2008207369B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817643A (en) * | 1992-08-21 | 1998-10-06 | Alpha-Beta Technology, Inc. | Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same |
WO2002058711A1 (fr) * | 2001-01-16 | 2002-08-01 | Sloan-Kettering Institute For Cancer Research | Glucane ameliorant une therapie |
US20060009419A1 (en) * | 2002-09-04 | 2006-01-12 | Ross Gordon D | Therapy-enhancing glucan |
WO2005018544A2 (fr) * | 2003-07-16 | 2005-03-03 | Sloan-Kettering Institute For Cancer Research | Glucane renforçateur de therapie |
WO2006119395A2 (fr) * | 2005-05-03 | 2006-11-09 | Biopolymer Engineering, Inc. | Compositions d'association d'agents therapeutiques, et leurs procedes d'utilisation |
Non-Patent Citations (8)
Title |
---|
CHEN ET AL: "Medicinal importance of fungal beta-(1->3), (1->6)-glucans", MYCOLOGICAL RESEARCH, ELSEVIER, GB, vol. 111, no. 6, 1 June 2007 (2007-06-01), pages 635 - 652, XP022163026, ISSN: 0953-7562 * |
CHEUNG N-K V ET AL: "Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 51, no. 10, 1 November 2002 (2002-11-01), pages 557 - 564, XP002297978, ISSN: 0340-7004 * |
HERLYN D ET AL: "Stimulation of monoclonal antibody-dependent macrophage-mediated cytotoxicity against human tumors by lentinan", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 7, no. 3, 1 January 1985 (1985-01-01), pages 332, XP023842271, ISSN: 0192-0561, [retrieved on 19850101] * |
HONG F ET AL: "Mechanism by which orally administered [beta]-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 2, 15 July 2004 (2004-07-15), pages 797 - 806, XP009125353, ISSN: 0022-1767 * |
KANEKO Y ET AL: "Activity of lentinan against cancer and AIDS", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, BIOSCIENCE EDIPRINT INC., CAROUGE-GENEVA, CH, vol. 5, no. 4, 1 January 1989 (1989-01-01), pages 203 - 213, XP009125324, ISSN: 0255-9625 * |
PELLEY R P ET AL: "Plants, polysaccharides and the treatment and prevention of neoplasia", CRITICAL REVIEWS IN ONCOGENESIS, BOCA RATON, FL, vol. 11, no. 3&4, 1 January 2000 (2000-01-01), pages 189 - 225, XP002963429, ISSN: 0893-9675 * |
PENNA C ET AL: "PULMONARY METASTASES NEUTRALIZATION AND TUMOR REJECTION BY IN VIVO ADMINISTRATION OF BETA GLUCAN AND BISPECIFIC ANTIBODY", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 65, 1 January 1996 (1996-01-01), pages 377 - 382, XP002924638, ISSN: 0020-7136 * |
VETVICKA V ET AL: "SOLUBLE BETA-GLUCAN POLYSACCHARIDE BINDING TO THE LECTIN SITE OF NEUTROPHIL OR NATURAL KILLER CELL COMPLEMENT RECEPTOR TYPE 3 (CD11B/CD18) GENERATES A PRIMED STATE OF THE RECEPTOR CAPABLE OF MEDIATING CYTOTOXICITY OF IC3B-OPSONIZED TARGET CELLS", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 98, no. 1, 1 July 1996 (1996-07-01), pages 50 - 61, XP001000371, ISSN: 0021-9738 * |
Also Published As
Publication number | Publication date |
---|---|
AU2008207369A1 (en) | 2008-09-11 |
EP1984004A2 (fr) | 2008-10-29 |
WO2007084661A2 (fr) | 2007-07-26 |
WO2007084661B1 (fr) | 2008-01-10 |
JP2009528267A (ja) | 2009-08-06 |
AU2008207369B2 (en) | 2009-12-17 |
WO2007084661A3 (fr) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL195937A0 (en) | Glucan preparation | |
DE602007002700D1 (en) | Interventionsfreies frac-system | |
EP2078282A4 (fr) | Coupons électroniques | |
EP2033216A4 (fr) | Électroadhérence | |
DE602007008085D1 (en) | Dihydropyrazolopyrimidinonderivate | |
DE602007014031D1 (en) | Luftreifensatz | |
DE602007002070D1 (en) | 2-pyrazincarboxamidderivate | |
EP1984004A4 (fr) | Glucane permettant d'améliorer une thérapie | |
DE602007003855D1 (en) | Isothermer reaktor | |
DE602007001601D1 (en) | Glasuntersuchung | |
DE602007006989D1 (en) | Spiropiperidinderivate | |
GB0624102D0 (en) | Boot-jacks | |
GB0612413D0 (en) | Rooflight | |
IL194490A0 (en) | Thiazolyl-dihydroquinazolines | |
AP2008004724A0 (en) | Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane | |
DE602007011622D1 (en) | Penem-prodrugs | |
EP2084019A4 (fr) | Grattoir a peinture | |
EP2024567A4 (fr) | Papier peint à base de terre | |
DK1989111T3 (en) | Satellitluftbremseapparat | |
DE502007001126D1 (en) | Eiten | |
GB0623080D0 (en) | Wallfence | |
GB0601584D0 (en) | Cosyhold headscarf | |
AU3514P (en) | ARCBENT Arctotis fastuosa | |
AU4914P (en) | CalflatGL Calothamnus quadrifidus | |
GB0609547D0 (en) | My Gogglebox |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080814 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100202 |
|
17Q | First examination report despatched |
Effective date: 20100527 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20121016 |